Our Investigators

Chairman's Office

Jay S. Skyler, M.D., Type 1 Diabetes TrialNet Chairman, University of Miami
Distinguished career in diabetes that spans more than four decades that includes founding and leading the University of Miami's Diabetes Metabolic Unit to international prominence.

Jay Sosenko, M.D., Type 1 Diabetes TrialNet Associate Chair for Epidemiology and Ethics, University of Miami
Primary author of a paper that was the first to show an association between diabetic sensory neuropathy and height.

Stephen E. Gitelman, M.D., Type 1 Diabetes TrialNet Principal Investigator, University of California San Francisco Children's Hospital
Pediatric endocrinologist and diabetes researcher who is working with scientists around the world to create new treatments to block autoimmune destruction of insulin-producing beta cells, improve current treatments, and ultimately prevent the disease.

Darrell Wilson, M.D., Type 1 Diabetes TrialNet Principal Investigator, Stanford University
Expansive career in pediatric endocrinology and diabetes includes current position as the Chief of Pediatric Endocrinology and Diabetes at the Lucile Packard Children's Hospital at Stanford.

Colorado

Connecticut

Kevan C. Herold, M.D., Type 1 Diabetes TrialNet Principal Investigator, Yale University School of Medicine
Well known in the field of type 1 diabetes research for being part of the team that was the first to report use of anti-CD3 monoclonal antibody, a treatment now in development.

Florida

Jennifer B. Marks, M.D., Type 1 Diabetes TrialNet Principal Investigator, University of Miami, Miller School of Medicine
Endocrinologist/diabetologist who sees patients, teaches, and conducts clinical research in several areas of diabetes, including prevention, treatment, and prevention of complications.

Desmond Schatz. M.D., Type 1 Diabetes TrialNet Principal Investigator, University of Florida College of Medicine
Well-known and published pediatric endocrinologist involved in type 1 diabetes research with a focus on the prediction, natural history, genetics, immunopatho-genesis and prevention of type 1 diabetes, as well as the management of type 1 diabetes in children and adolescents.

Italy

Responsible for the Natural History Study and Oral Insulin Study in subjects at risk for new onset type 1 diabetes. Heads the network of TrialNet clinical sites in Italy and Germany.

Minnesota

Antoinette Moran, M.D., Type 1 Diabetes TrialNet Regional Principal Investigator, University of Minnesota
Highly published author on diabetes complications, who specializes in clinical trials to prevent or delay the onset of type 1 diabetes; co-directs the assessment of metabolic endpoints to improve the efficacy of islet transplantation of type 1 diabetes.

New York

Robin Goland, M.D., Type 1 Diabetes TrialNet Principal Investigator, Columbia University
Noted clinical investigator who is part of the team who established the Naomi Berrie Diabetes Center and has guided it to a premier, family-focused diabetes care and research facility.

Turku, Finland

Olli Simell, M.D., Type 1 Diabetes TrialNet Principal Investigator, University of Turku, Turku, Finland
Physician, researcher, and instructor of international stature, and member of a dozen Finnish and international scientific advisory and review boards.

United Kingdom

Penelope Bingley, M.D., Type 1 Diabetes Principal Investigator, University of Bristol. Member of TN01 Natural History Study Chair Committee and Chair of Dried-Blood Spot Ancillary Study Committee. Professor of Diabetic Medicine at the University of Bristol and Honorary Consultant Physician at Southmead Hospital and Bristol Royal Infirmary, Bristol. Heads the network of TrialNet clinical sites in the United Kingdom.

Washington

Carla Greenbaum, M.D., Type 1 Diabetes TrialNet Principal Investigator and Vice Chair, Benaroya Research Institute
Leader in clinical investigations and trials to prevent or intervene with the diabetes autoimmune process and well-known as an expert in designing research protocols for children with diabetes.

TrialNet is a network of 21 Clinical Centers working in cooperation with screening sites throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Australia, and New Zealand. This network is dedicated to the study, prevention, and early treatment of type 1 diabetes. Learn More >